Epilepsy trials in United States
208 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.
- No phaseTaking peopleEvaluation and Treatment of Neurosurgical Disorders
- Where
- Bethesda
- Age
- 4 years to 99 years
- People
- 5,000
- Run by
- National Institute of Neurological Disorders and Stroke (NINDS)
See details and how to joinNCT00060541 - No phaseTaking peopleTumor Related Epilepsy
- Where
- Bethesda
- Age
- 8 years to 99 years
- People
- 100
- Run by
- National Institute of Neurological Disorders and Stroke (NINDS)
See details and how to joinNCT02639325 - No phaseEnrolling by invitationStudy of Direct Brain Recording and Stimulation for Memory Enhancement
- Where
- Bethesda
- Age
- 18 years to 65 years
- People
- 200
- Run by
- National Institute of Neurological Disorders and Stroke (NINDS)
See details and how to joinNCT04095026 - Phase 3Taking peopleInvestigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
- Where
- Austin, Baltimore, Bethesda, Boise, Columbia, Dallas, Durham, Hackensack, Jacksonville, Lexington, New Brunswick, New Orleans, Orlando, Palo Alto, Philadelphia, Rochester, Tampa, The Bronx, Wellington, Winchester, Winston-Salem
- Age
- 4 years to 55 years
- People
- 252 worldwide
- Run by
- SK Life Science, Inc.
See details and how to joinNCT05219617 - Phase 3Taking peopleStudy Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
- Where
- Asheville, Atlanta, Bethesda, Birmingham, Boise, Cleveland, Fort Wayne, Gulf Breeze, Hackensack, Livingston, New York, Palmdale, Philadelphia, Richmond, Springfield, The Bronx
- Age
- 18 years to 75 years
- People
- 333 worldwide
- Run by
- Rapport Therapeutics Inc.
See details and how to joinNCT07563881 - Phase 3Taking peopleStudy Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
- Where
- Bentonville, Chicago, Colorado Springs, Honolulu, Houston, Huntsville, Maitland, Miami, Nashville, New York, Omaha, Raleigh
- Age
- 18 years to 75 years
- People
- 312 worldwide
- Run by
- Rapport Therapeutics Inc.
See details and how to joinNCT07594119 - No phaseEnrolling by invitationNeural Mechanisms for Stopping Ongoing Speech Production (Study 2)
- Where
- Pittsburgh
- Age
- 8 years to 26 years
- People
- 12
- Run by
- University of Pittsburgh
See details and how to joinNCT07713706 - No phaseTaking peopleGenetic Markers of Cardiovascular Disease in Epilepsy
- Where
- Rochester
- Age
- 18 years to 50 years
- People
- 600
- Run by
- Mayo Clinic
See details and how to joinNCT02824822 - Phase 3Taking peopleA Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
- Where
- Akron, Amherst, Ann Arbor, Atlanta, Aurora, Austin, Baltimore, Bethesda, Boise, Boys Town, Charleston, Charlotte, Chestnut Hill, Cleveland, Clinton, Columbus, Detroit, Durham, East Lansing, El Paso, Grand Rapids, Hackensack, Honolulu, Houston, Indianapolis, Jacksonville, Kansas City, Lexington, Little Rock, Los Angeles, Miami, Milwaukee, Mobile, Orange, Orlando, Pensacola, Philadelphia, Phoenix, Pittsburgh, Port Charlotte, Sacramento, Salt Lake City, San Antonio, Seattle, Springfield, St Louis, Suwanee, Syracuse, Tampa, Tucson, Virginia Beach, Weston, Winston-Salem, Woodmere, Worcester
- Age
- 12 years and over
- People
- 160 worldwide
- Run by
- Xenon Pharmaceuticals Inc.
See details and how to joinNCT05667142 · EU 2022-502286-16-00 - Phase 3Taking peopleA Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
- Where
- Austin, Bethesda, Boise, Cleveland, Columbus, Detroit, Downey, Durham, Gulf Breeze, Hackensack, Jacksonville, Little Rock, Los Angeles, Nashville, Orange, Portland, Salt Lake City, Springfield, Woodmere
- Age
- 18 years and over
- People
- 360 worldwide
- Run by
- Xenon Pharmaceuticals Inc.
See details and how to joinNCT05716100 · EU 2022-502281-25-00 - Phase 3Enrolling by invitationAn Open-label Study of XEN1101 in Epilepsy
- Where
- Akron, Ann Arbor, Aurora, Austin, Baltimore, Bethesda, Boise, Boston, Buffalo, Burnsville, Charlotte, Cleveland, Columbus, Detroit, Durham, East Lansing, El Paso, Grand Rapids, Hackensack, Honolulu, Indianapolis, Jacksonville, Kansas City, Lexington, Little Rock, Los Angeles, Miami, Milwaukee, Nashville, New York, Orange, Orlando, Pensacola, Philadelphia, Phoenix, Portland, Raleigh, Roanoke, Sacramento, Salt Lake City, San Antonio, Scarborough, Seattle, St Louis, Syracuse, Tampa, The Bronx, Tucson, Virginia Beach, Weston, Worcester
- Age
- 12 years and over
- People
- 880 worldwide
- Run by
- Xenon Pharmaceuticals Inc.
See details and how to joinNCT05718817 · EU 2022-502282-24-00 - No phaseTaking peopleMapping of Human Cognition
- Where
- Houston
- Age
- 18 years to 75 years
- People
- 75
- Run by
- The University of Texas Health Science Center, Houston
See details and how to joinNCT05989893 - Phase 1/2Taking peopleASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
- Where
- Ann Arbor, Durham, Memphis, Philadelphia, Rochester, Seattle
- Age
- 2 years to 12 years
- People
- 32 worldwide
- Run by
- Ionis Pharmaceuticals, Inc.
See details and how to joinNCT07531745 - Phase 2/3Taking peopleA Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy
- Where
- Atlanta, Boise, Chicago, Cincinnati, Dallas, Grand Rapids, Hawthorne, Honolulu, Lake Success, Lexington, Los Angeles, New Brunswick, New Haven, New York, Philadelphia, Phoenix, Portland, Roanoke, Sacramento, Savannah, Tampa, Virginia Beach, Winchester
- Age
- 10 years and over
- People
- 260
- Run by
- Jazz Pharmaceuticals
See details and how to joinNCT07723963 - No phaseTaking peopleHOBSCOTCH-YOUTH and Young Adults
- Where
- Lebanon
- Age
- 13 years to 29 years
- People
- 300
- Run by
- Dartmouth-Hitchcock Medical Center
See details and how to joinNCT07735715 - Phase 3Taking peopleStudy of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
- Where
- Aurora, Birmingham, Boston, Buffalo, Charlotte, Chicago, Dallas, Detroit, Durham, Great Neck, Houston, Iowa City, Lebanon, Little Rock, Los Angeles, Miami, Milwaukee, New Orleans, New York, Orange, Palo Alto, Philadelphia, Phoenix, Portland, Sacramento, Salt Lake City, San Diego, San Francisco, Seattle, St Louis, Syracuse, Tucson, Washington D.C., Winston-Salem
- Age
- 18 years to 75 years
- People
- 88
- Run by
- Neurona Therapeutics
See details and how to joinNCT05135091 - No phaseNot yet taking people in United StatesLily's Grace Temporal Interference
- Where
- Madison
- Age
- 18 years to 75 years
- People
- 24
- Run by
- University of Wisconsin, Madison
See details and how to joinNCT07520955 - Phase 1Taking peopleInvestigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy
- Where
- Bethesda
- Age
- 18 years to 60 years
- People
- 40
- Run by
- National Institute of Neurological Disorders and Stroke (NINDS)
See details and how to joinNCT02531880 - Phase 3Taking peopleA Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
- Where
- Ann Arbor, Atlanta, Austin, Birmingham, Chicago, Cincinnati, Cleveland, Columbus, Dallas, Durham, Hackensack, Kissimmee, Little Rock, Los Angeles, Louisville, Marlboro, Memphis, Milwaukee, Morrisville, New Haven, New York, Omaha, Orange, Philadelphia, Salt Lake City, San Francisco, Seattle, Wilmington, Winston-Salem, Winter Park
- Age
- 2 years and over
- People
- 150 worldwide
- Run by
- Epygenix
See details and how to joinNCT04462770 · EU 2024-518628-57-00 - No phaseTaking peopleRare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
- Where
- Sioux Falls
- People
- 20,000
- Run by
- Sanford Health
See details and how to joinNCT01793168 - No phaseTaking peoplePET/MRI/EEG Imaging Study in Epilepsy
- Where
- Charlestown
- Age
- 18 years and over
- People
- 30
- Run by
- Massachusetts General Hospital
See details and how to joinNCT06974305 - No phaseNot yet taking people in United StatesHigh-Intensity Focused Ultrasonic Ablation of the Centromedian Thalamic Nucleus for Treatment of Medically Refractory Generalized Epilepsy in Patients Ages 18 Years to 89 Years
- Where
- Portland
- Age
- 18 years to 89 years
- People
- 10
- Run by
- Oregon Health and Science University
See details and how to joinNCT07803692 - No phaseTaking peopleEpilepsy Seizure Detection With Innovative Tripolar EEG (tEEG)
- Where
- Boston, Phoenix
- Age
- 6 years and over
- People
- 90
- Run by
- CREmedical
See details and how to joinNCT05944692 - Phase 2Enrolling by invitationSPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures
- Where
- Asheville, Kissimmee, Philadelphia, Port Charlotte, Rochester, Tucson, West Hills
- Age
- 18 years and over
- People
- 100 worldwide
- Run by
- Supernus Pharmaceuticals, Inc.
See details and how to joinNCT07141329 · EU 2026-526361-15-00 - No phaseEnrolling by invitationAn Examination of Cognitive and Sensorimotor Processes in Patients With Epilepsy
- Where
- Great Neck
- Age
- 5 years and over
- People
- 450
- Run by
- Northwell Health
See details and how to joinNCT00859794